Dr Reddy's Lab launches Fexofenadine HCI, Pseudoephedrine HCI Extended-Release Tablets
19th Jul 2019

Dr. Reddy's Laboratories has launched Fexofenadine HCI 60 mg and Pseudoephedrine HCI 120 mg Extended-Release Tablets, USP, an over-the-counter (OTC) store-brand equivalent of Allegra-D 12 HR Allergy and Congestion Extended-Release Tablets, in the United States market, as approved by the U.S. Food and Drug Administration (USFDA).

According to IRi, the Allegra-D 12 HR Allergy and Congestion Extended-Release Tablets brand and generic had U.S. sales of approximately $44 million MAT for the most recent twelve months ending in May 2019. The company’s OTC Fexofenadine HCI 60 mg and Pseudoephedrine HCI 120 mg Extended-Release Tablets, USP are available in 20- and 30-count sizes.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.